Psychotropic medications from natural products: A review of promising research and recommendations

Alternative Therapies in Health and Medicine

Volumn 6, Issue 3, 2000, Pages 36-60

  Lake, James ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; ASCORBIC ACID; AYURVEDIC DRUG; BR 16A; CANNABIDIOL; CANNABIS; CHAMOMILE; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FOLIC ACID; GARLIC EXTRACT; GINSENG EXTRACT; GLYCINE; HERBACEOUS AGENT; KAVA; MAGNESIUM; PAEONIA RADIX; PHENYLALANINE; PHOSPHATIDYLSERINE; PSYCHOTROPIC AGENT; PYRIDOXINE; ROSMARINUS OFFICINALIS EXTRACT; S ADENOSYLMETHIONINE; THIAMINE; TRYPTOPHAN; TYROSINE; UNINDEXED DRUG; WITHANIA SOMNIFERA EXTRACT;

ANXIETY; CHINESE MEDICINE; DRUG ACTIVITY; DRUG INDUSTRY; GINKGO BILOBA; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; MENTAL DISEASE; NEUROPHARMACOLOGY; REVIEW; SEIZURE; SUBSTANCE ABUSE; VALERIANA OFFICINALIS;

ANGIOSPERMS; HUMANS; MENTAL DISORDERS; PHYTOTHERAPY; PSYCHOTROPIC DRUGS; SEIZURES; SUBSTANCE-RELATED DISORDERS;

EID: 0033944967     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Andrews G, German, G, Eisenberg L, De Girolamo G, Sartorius N. Conclusions: cure relief and comfort. In: Sartorius N, De Girolamo G, eds. Treatment of Mental Disorders: A Review of Effectiveness. Washington, DC: APA Press; 1993:463-174.
2. Cott J. Medicinal plants and dietary supplements: sources for innovative treatments or adjuncts? Psychopharmacol Bull. 1995;31:131-137.
3. Naranjo P. The urgent need for the study of medicinal plants. In: Schultes R, Reis S, eds. Ethnobotany: Evolution of a Discipline. Portland, Ore: Dioscorides Press; 1995:362-368.
4. Borris R. Natural products research: perspectives from a major pharmaceutical company. J Ethnopharmacol. 1996:51(1-3):29-38.
5. Turner D. Natural product source material use in the pharmaceutical industry: the Glaxo experience. J Ethnopharmacol. 1996;51:39-44.
6. Duke JA. Commentaryæ Novel psychotherapeutic drugs: a role for ethnobotany. Psychopharmacol Bull. 1995;31(1)177-184.
7. Phillipson JD, Anderson LA. Ethnopharmacology and western medicine. J Ethnopharmacol. 1989;25(1):61-72.
8. Mowrey D. The Scientific Validation of Herbal Medicine. New Canaan, Conn: Keats Publishing; 1986.
9. Sharma HM. Phytochemical synergism: beyond the active ingredient model. Altern Ther Clin Practice. 1997;May/June:91-96.
10. Etkin N. Ethnopharmacology: biological and behavioral perspectives in the study of indigenous medicines. In: Johnson T, Sargent C, eds. Medical Anthropology: Contemporary Theory and Method. New York, NY: Praeger; 1990:149-158.
11. Hughes C. Ethnopsychiatry. In: Johnson T. Sargent C, eds. Medical Anthropology: Contemporary Theory and Method. New York, NY: Praeger; 1990:132-148.
12. Romanucci-Ross L, Tancredi L, Weisstub D, Want J, Rodine L. Psychiatry in modern medicine: problematics for its transcultural applications. In: Romanucci-Ross L, Moerman D, Tancredi L, eds. The Anthropology of Medicine: From Culture to Method. New York, NY: Bergar and Garvey; 1991:267-370.
13. Tseng W. Overview: culture and psychopathology. In: Tseng W. Streltzer J, eds. Culture and Psychopathology: A Guide to Clinical Assessment. Philadelphia, Pa: Brunner/Mazel, Inc; 1997:1-27.
14. DeSmet P. An Introduction to herbal pharmacoepidemiology. J Ethnopharmacal. 1993;38:197-208.
15. Hoffman A. Botanical (Herbal) medicine in healthcare: a review from a regulatory perspective. Pharm News. 1996;3(1):23-25.
16. Farnsworth NR. Ethnopharmacology and future drug developoment: the north American experience. J Ethnopharmacol. 1993;38:145-152.
17. Cox PA. The ethnobotanical approach to drug discovery: strengths and limitations. In: Ethnobotany and the Search for New Drugs. Ciba Foundation Symposium 185. Chichester, England: Wiley; 1994:25-41.
18. Marderosian A. Classification by pharmacological action. In: Stickley G, ed. Natural Product Medicine: A Scientific Guide to Foods, Drugs, Cosmetics. Philadelphia, Pa: George F. Stickley Co; 1988:23-51.
19. Evans WC. Biological and geographical sources of drugs. In: Evans WC, ed. Trease and Evans' Pharmacognosy. 13th ed. Devon, England: Bailliere Tindall; 1989:61-67.
20. Vogel H. Similarities between various systems of traditional medicine: considerations for the future of ethnopharmacology. J Ethnopharmacol. 1991;35(2):179-190.
21. First M, ed. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA Press; 1994.
22. Lin K, Poland, R., Silver, B. Overview: the interface between psychobiology and ethnicity. In: Lin K, Poland R, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC: APA Press; 1993:11-36.
23. Palmer G. Miller JA. The search for new anti-epileptic drugs, part I: focus on excitatory and inhibitory transmission processes. Pharma News. 1996;3(1):7-11.
24. Abdul-Ghani AS. Anticonvulsant effects of some arab medicinal plants. J Crude Drug Res. 1987;25:39-43.
25. Shanmugasundaram ERB, Akbar M, Shanmugasundaram KR. Brahmighritham, an Ayurvedic herbal formula for the control of epilepsy. J Ethnopharmacol. 1991;33:369-276.
26. N'gouemo P, Nguemby-Bina C, Baldy-Moulinier M. Some neuropharmacological effects of an ethanloic extract of Maprounea africana in rodents. J Ethnopharmacol. 1994;43:161-166.
27. Winick C. Epidemiology. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance Abuse: A Comprehensive Textbook. 3rd ed. Philadelphia, Pa: Williams and Wilkins; 1997:10-15.
28. Rasmussen P. A role for phytotherapy in the treatment of benzodiazepine and opiate drug withdrawal. Eur J Herbal Med. 1996;3(1):12-21.
29. Yoshikawa M, Murakami T, Yoshizumi S, Murakami N, Yamahara J, Matsuda H. Bioactive saponins and glycosides...from seeds of Camellia japonica L: structures and inhibitory activity on alcohol absorption. Chem Pharm Bull. 1996;44:1899-1907.
30. Yoshikawa M. Bioactive saponins and glycosides VI...:the strucure-requirement in oleaniolic acid glucuronide-saponins for the inhibitory activity. Chem Pharm Bull. 1996;44:1915-1922.
31. Kim HS. Blockade by ginseng total saponin of the development of methamphetamine reverse tolerance and dopamine receptor supersensivity in mice. Planta Medica. 1995;61:22-25.
32. Godfrey J. Delirium tremens: treated by Cannabis indica. The Eclectic Medical Journals. 1996;June/JulyII(3):12.
33. Kulkarni SK. Inhibition of morphine tolerance and dependence by Withania somnifera in mice. J Ethnopharmacol. 1997;57:213-217.
34. Karno M, Jenkins J. Cultural considerations in the diagnosis of schizophrenia and related disorders and psychotic disorders not otherwise classified. In: Steering Committee, NIMH Group on Culture and Diagnosis. DSM-IV Casebook for Cultural Psychiatry. Washington, DC: NIMH: 1994:83-90.
35. Sartorius N. Cultural factors in the etiology of schizophrenia. In: Stefanis CN, ed. Psychiatry: A World Perspective. Vol 4. Elsevier Science Publishers; 1990:33-40.
36. Cohen A. Prognosis for schizophrenia in the third world: a re-evaluation of cross-cultural research. Culture, Medicine and Psychiatry. 1992;16:53-75.
37. Sartorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol Med. 1986;16:909-928.
38. Marder S, Van Putten T. Anti-psychotic medications. In: Schatzberg AF, Nemeroff CB. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: APA Press; 1995:247-262.
39. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC. Preliminary investigation of high-dose oral glycerine on serum levels and negative symptoms in schizophrenia: an open-labeled trial. Biol Psychiatry. 1996;39:213-215.
40. Zuardi AW, Rodrigues JA, Cunha JM. Effects on cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology. 1991;104:260-264.
41. Chung IW, Kim YS, Ahn JS, et al. Pharmacologic profile of natural products used to treat psychotic illnesses. Psychopharmacol Bull. 1995;31:139-145.
42. Ramu MG, Venkataram BS, Mukundan H, Shankara MR, Leelavathy S, Janakiramaiah N. A controlled study of Ayurvedic treatment in the acutely ill patients with schizophrenia (Unmada): rationale and results. NIMHANS Journal. 1992;10(1):1-16.
43. Andrews G, German G, Eisenberg L, De Giorolamo G, Sartorius N. Conclusions: cure, relief and comfort. In: Sartorius N, De Girolamo G, eds. Treatment of Mental Disorders: A Review of Effectiveness. Washington, DC: APA Press; 1993:463-474.
44. Sclazo R, Mitchell ND. Therapeutic botanical protocol for Alzheimer's disease. Protocol J Botanical Med. 1996;2(1):120-131.
45. Maurer K, Ih R, Dierks T, Frolich L Clinical efficacy of Ginkgo biloba special extract Egb-761 in dementia of the Alzheimer type. J Psychiatr Res. 1997;31:645-655.
46. Kanowski S, Hermann WM. Proof of efficacy of the Ginkgo biloba special extract Ebg761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29:47-56.
47. Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull. 1995;31:1.
48. Itil T, Ahmed I, LeBars P, Itil K. The pharmacological effects of Ginkgo biloba (GB), a plant extract, on the brain in comparison to Tacrine. Psychopharmacol Bull. 1996;32:459.
49. Moriguchi T, Moriguchi T, Saito H, Nishiyama N. Aged garlic extract prolongs longevity and improves spatial memory deficit in senescence-accelerated mouse. Biol Pharm Bull. 1996;19:305-307.
50. Mastrogiacomo F. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Ann Neurol. 1996;39:585-591.
51. Yabe T, Toriizuka K, Yamada H. Kami-untan-to (KUT) improves cholinergic deficits in aged rats. Phytomedicine. 1996;2:253-258.
52. Yabe T, Yamada H. Kami-Untan-to enhances choline acetyltransferase and nerve growth factor mRNA levels in brain-cultured cells. Phytomedicine. 1996/97;3:361-367.
53. Ohta H, Nishi K, Matsumoto K, Shimizu M, Watanabe H. Paeoniflorin improves learning deficit in 4-arm baited radial maze performance in rats with unilateral nucleus basalis magnocellularis lesion. Phytomedicine. 1994;1:117-121.
54. Bhattcharya SS. Effect of Mentat, a herbal formulation, on experimental models of Alzheimer's disease and central cholinergic markers in rats, Fitoterapia. 1995;66:216-222.
55. Tusuda T. Reinforcement effects of Boschniakia rossica on discrimination learning in cholinergic lesions in rats. J Ethnopharmacol. 1994;44:67-71.
56. Nishiyma N. An herbal prescription, S-113m, consisting of Biota, Ginseng, and Schizandra, improves learning performance in senescence accelerated mouse. Biol Pharm Bull. 1996;19:388-393.
57. Kidd P. Phosphatidylserine: membrane nutrient for memory: a clinical and mechanistic assessment. Altern Med Rev. 1996;1(2):70-84.
58. Brown D. Dementia and age-related cognitive decline. Condition-Specific Monograph Series. Portland, Ore: Natural Product Research Consultants; 1997.
59. Pinder R. Why more anti-depressants? Pharm News. 1996;3(4):11-14.
60. Ozturk Y. Aydin S, Beis F, Baser KHC, Berberoglu H. Effects of hypericum perforatum L. and H. Calcycinum L extract on the CNS in mice. Phytomedicine. 1996;III(2):139-146.
61. St. John's Wort extract and seasonal affective disorders. Q Rev Nat Med. 1995; Winter:273-274.
62. Delle, et al. Presented at 6th World Congress of Biological Psychiatry. Nice, France, June 22-27, 1997. Abstract 90-56.
63. Laakmann G, Schule C, Baghai T, Kieser M. St John's Wort in mild to moderate depression: the relevance of hyperforin for clinical efficacy. Pharmacopsychiatry. 1998;31(suppl 1):54-59.
64. Muller WE, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI-160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997;30(suppl 2):102-107.
65. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's Wort for depression: an overview and meta-analysis of randomized clinical trials. Br Med J. 1996;August:253-258.
66. Reichert R. St. John's Wort extract as a tricyclic medication substitute for mild to moderate depression. Q Rev Nat Med. 1995;275-278.
67. Ernst E. St. John's Wort: An anti-depressant? A Systematic crieteria-based review. Phytomedidne. 1995;2(1):67-71.
68. Brown D. Gingko biloba extract for resistant depressant. Q Rev Nat Med. 1994;Fall:211-212.
69. Bell KM, Potkin SG. Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl 1994;154:15-18.
70. Criconia L, Araquistain J, Daffina F, Bordino M. Results of treatment with S-adenosyl-L-methionine in patients with major depression and internal illnesses. Curr Ther Res. 1994;55:666-674.
71. DeVanna M. Rigamonti R. Oral S-adenosyl methionine in depression. Curr Ther Res. 1992;52:478-485.
72. Leifer A, Costarella L, Alakananda D. Therapeutic approaches to affective mood disorder. Protocol J Botanical Med. 2:1.
73. Ernst E, Rand JI, Stevinson C. Complementary therapies for depression: an overview. Arch Gen Psychiatry. 1998;55:1026-1032.
74. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St John's Word extract LI160 versus imiprimine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997;30(suppl 2):81-85.
75. Wheatley D. LI-160, an extract of St John's Wort, versus amitriptyline in mildly to moderately depressed outpatients: a controlled 6-week clinical trial. Pharmacopsychiatry. 1997;30(suppl):77-80.
76. Harrer G, Witte B, Kaptan T, Podzuweit H, Schmidt U. Treatment of mild/moderate depressions with hypericum. Phytomedidne. 1994;1:3-8.
77. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's Word for depression: an overview and meta-analysis of randomised clinical trials. Br Med J. 1996;313:253-258.
78. Ernst E. St John's Wort, and antidepressant? A systematic, criteria-based review. Phytomedicine. 1995;2:67-71.
79. Schubert H. Depressive epsiode primarily unresponsive to therapy in elderly patients: efficacy of Ginkgo biloba extract (Egb 761) in combination with antidepressants. Geriatr Forsch. 1993;3:43-53.
80. Thomson J, Rankin H, Ashcroft GW, Yates CM, McQueen JK, Cummings SW. The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med. 1982;12:741-751.
81. McGrath RE, Buckwald B, Resnick EV. The effect of L-tryptophan on seasonal affective disorder. J Clin Psychiatry. 1990;51:162-163.
82. Rao B, Broadhurst AD. Tryptophan and depression. Br Med J. 1976;1(6007):460. Letter.
83. Gelenberg AJ, Wojcik JD, Growdon JH, Sved AF, Wurtman RJ. Tyrosine for the treatment of depression. Am J Psychiatry. 1980;137:622-623.
84. Buist RA. The therapeutic predictability of tryptophan and tyrosine in the treatment of depression. Int Clin Nutr Rev. 1983;3(2):1-3.
85. Mann J, Peselow ED, Snyderman S, Gershon S. D-phenylalanine in edogenous depression. Am J Psychiatry. 1980;137:1611-1612.
86. Beckmann H, Athen D, Olteanu M, Zimmer R. DL-phenylalanine versus imipramine: a double-blind controlle study. Arch Psychiatr Nervenkr. 1979;227(1):49-58.
87. Russ CS. Vitamin B6 status of depressed and obsessive-compulsive patients. Nutr Rep Int. 1983;27:867-873.
88. Stewart JW, Harrison W, Quitkin F, Baker H. Low B6 status of depressed and obsessive-compulsive patients. Biol Psychiatry. 1984;19:613-616.
89. Ghadirian AM, Ananth J, Engelsmann F. Folic acid deficiency and depression. Pychosomatics. 1980;21:926-929.
90. Howard JS. Folate deficiency in psychiatric practice. Psychosomatics. 1975;16:112-115.
91. Hector M, Burton JR. What are the psychiatric manifestations of vitamin B12 deficiency? J Am Geriatr Soc. 1988;36:1105-1112.
92. Geaga K, Ananth J. Response of a psychiatric patient to vitamin B12 therapy. Dis Nerv System. 1975;36:343-344.
93. Milner G. Ascorbic acid in chronic psychiatric patients: a controlled trial. Br J Psychiatry. 1963;109:294-299.
94. Frizel D, Coppen A, Marks V. Plasma magnesium and calcium in depression. Br J Psychiatry. 1969;115:11375-1377.
95. Shealy CN, et al. Magnesium deficiency in depression and chronic pain. Magnesium Trace Elem. 1990;9:333.
96. Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH. Inositol treatment in psychiatry. Psychopharmcol Bull. 1995;31:167-175.
97. Oshima Y. Antidepressant principles of Valeriana fauriei roots. Chem Pharm Bull. 1995;43:169-170.
98. Gerson S. Therapeutic approaches to anxiety disorders. Protocol J Botanical Med. 1995;Summer:20-45.
99. Reichert R. Treatment of anxiety with Kava-kava. Q Rev Nat Med. 1996;Winter:249-250.
100. Lehmann E. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin: a double-blind placebo-controlled study of four weeks treatment. Phytomedicine. 1996:III(2):113-119.
101. Kinzler E, Kromer J, Lehmann E. Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis: double blind study with placebos over 4 weeks [in German]. Arzneimittelforschung. 1991;41:584-588.
102. Warnecke G. Psychosomatic disorders in the female clinacteric: clinical efficacy and tolerance of kava extract WS-1490. Fortsch Med. 1991;109:119-122.
103. Volz HP. Kava-kava extract WS-1490 versus placebo in anxiety disorders: a randomized placebo-controlled 25 week outpatient trial. Pharmacopshychiatry. 1997;30:1-5.
104. Woelk H, et al. Treatment of patients suffering from anxiety: double-blind study: kava special extract versus benzodiazepines. Ztschr Allegemeinmed. 1993;69:271-277.
105. Brown D. Valerian root: non-addictive alternative for insomnia and anxiety. Rev Nat Med. 1994;Fall:221-224.
106. Bhattacharya SK. Mitra SK. Anxiolytic activity of Panax genseng roots: an experimental study. J Ethnopharmacol. 1991;34:87-92.
107. Viola H, Wasowski C, Levi de Stein M. Apigenin, a component of M. recutita flowers, is a central benzodiazepine receptor ligand with anxiolytic effects. Planta Medica. 1995;61:213-2:6.
108. Viola H, Wolfman C, Levi de Stein M. Isolation of pharmacologically active benzodiazepine receptor ligants from Tilia tomentosa (Tiliaceae). J Ethnopharmacol. 1994;44:47-53.
109. Elisha E, et al. Effects of Jasminum officinale flowers on CNS of the mouse. Int J Crude Drug Res. 1988;26:221-227.
110. Bishayee A, et al. Mechanism of anti-stress activity of Mikania cordata root extract in albino mice. Int J Pharmacognosy. 1995;33:215-221.
111. Weniger B. Interest and limitation of a global ethnopharmacological survey. J Ethnopharmacol. 1991;32:37-41.
112. Lewis W. New concepts in medical and dental ethnobotany. In: Evans Schultes R, Von Reis S, eds. Ethnobotany: Evolution of a Discipline. Portland, Ore: Timber Press: 1995:303-310.